Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline.

Abstract

OBJECTIVE:

The aim was to formulate practice guidelines for the diagnosis and treatment of hyperprolactinemia.

PARTICIPANTS:

The Task Force consisted of Endocrine Society-appointed experts, a methodologist, and a medical writer.

EVIDENCE:

This evidence-based guideline was developed using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system to describe both the strength of recommendations and the quality of evidence.

CONSENSUS PROCESS:

One group meeting, several conference calls, and e-mail communications enabled consensus. Committees and members of The Endocrine Society, The European Society of Endocrinology, and The Pituitary Society reviewed and commented on preliminary drafts of these guidelines.

CONCLUSIONS:

Practice guidelines are presented for diagnosis and treatment of patients with elevated prolactin levels. These include evidence-based approaches to assessing the cause of hyperprolactinemia, treating drug-induced hyperprolactinemia, and managing prolactinomas in nonpregnant and pregnant subjects. Indications and side effects of therapeutic agents for treating prolactinomas are also presented.

• Authors: Shlomo Melmed, Felipe F Casanueva, Andrew R Hoffman, David L Kleinberg, Victor M Montori, Janet A Schlechte, John A H Wass, Endocrine Society
• Journal: The Journal of clinical endocrinology and metabolism (J Clin Endocrinol Metab) Vol. 96 Issue 2 Pg. 273-88 (Feb 2011) ISSN: 1945-7197 [Electronic] United States
• PMID: 21296991 (Publication Type: Journal Article, Practice Guideline, Research Support, Non-U.S. Gov't, Review)

Topics

• Adult
• Female
• Humans
• Pregnancy
• Evidence-Based Medicine
• Hyperprolactinemia (chemically induced, diagnosis, etiology, pathology)
• Pituitary Neoplasms (complications, drug therapy)
• Prolactinoma (complications, drug therapy)